Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

PARIS--(BUSINESS WIRE)--Regulatory News:

ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30^th 2022:

- 44,453 shares

- € 320,248.35

- Number of executions on buy side on semester: 474

- Number of executions on sell side on semester: 454

- Traded volume on buy side on semester: 46,043 shares for € 311,966.95

- Traded volume on sell side on semester: 63,621 shares for € 440,978.86

As a reminder:

• the following resources appeared on the last half year statement on 31 December 2021 on the liquidity account:

- 62,031 shares

- € 191,956.52

- Number of executions on buy side on semester: 264

- Number of executions on sell side on semester: 42

- Traded volume on buy side on semester: 67,876 shares for € 445,195.95

- Traded volume on sell side on semester: 5,845 shares for € 37,412.21

• the following resources appeared on the liquidity account when the activity started:

- 0 shares

- € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22^nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the risk of bleeding, particularly intracerebral hemorrhage.

In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, at the European Stroke Organisation Conference (ESOC 2022), confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients.

Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris, since November 2021 (ISIN: FR0014005OJ5 – ALACT).

For further information, please go to www.acticor-biotech.com

Appendix

	Buy Side			Sell Side
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	474	46,043	311,966.95	454	63,621	440,978.86
03/01/2022	5	154	705.32	3	558	2,577.96
04/01/2022	-	-	-	3	130	611.00
05/01/2022	-	-	-	9	390	1,856.40
06/01/2022	1	1	4.70	-	-	-
07/01/2022	1	116	545.20	1	107	513.60
10/01/2022	-	-	-	3	273	1,310.40
11/01/2022	-	-	-	3	23	110.40
12/01/2022	-	-	-	1	477	2,289.60
13/01/2022	-	-	-	19	2,400	12,048.00
14/01/2022	-	-	-	18	2,436	13,860.84
17/01/2022	-	-	-	21	1,263	7,830.60
18/01/2022	-	-	-	25	4,702	31,973.60
19/01/2022	-	-	-	3	800	5,520.00
20/01/2022	3	1,000	6,800.00	-	-	-
21/01/2022	10	801	5,126.40	1	1	6.50
24/01/2022	8	1,700	10,234.00	-	-	-
25/01/2022	12	1,492	8,847.56	-	-	-
26/01/2022	7	608	3,496.00	-	-	-
27/01/2022	-	-	-	2	40	236.00
28/01/2022	13	633	3,690.39	-	-	-
31/01/2022	3	167	968.60	1	60	354.00
01/02/2022	4	92	539.12	5	896	5,376.00
02/02/2022	5	401	2,438.08	6	1,056	6,504.96
03/02/2022	2	709	4,211.46	2	350	2,205.00
04/02/2022	4	300	1,830.00	-	-	-
07/02/2022	5	567	3,453.03	-	-	-
08/02/2022	7	490	2,959.60	1	1	6.06
09/02/2022	6	670	4,053.50	-	-	-
10/02/2022	6	210	1,264.20	1	1	6.04
11/02/2022	4	200	1,204.00	3	148	896.88
14/02/2022	4	326	1,939.70	1	1	6.02
15/02/2022	5	499	2,919.15	1	1	5.90
16/02/2022	2	46	266.80	-	-	-
17/02/2022	4	401	2,325.80	1	1	5.80
18/02/2022	9	595	3,433.15	1	1	5.80
21/02/2022	3	306	1,744.20	-	-	-
22/02/2022	3	400	2,240.00	4	315	1,795.50
23/02/2022	1	25	141.00	10	1,285	7,388.75
24/02/2022	4	1,700	9,639.00	1	500	2,870.00
25/02/2022	2	309	1,761.30	3	481	2,760.94
28/02/2022	-	-	-	13	2,217	12,969.45
01/03/2022	-	-	-	13	3,854	24,241.66
02/03/2022	-	-	-	11	4,000	28,960.00
04/03/2022	-	-	-	9	3,500	28,000.00
07/03/2022	-	-	-	9	2,000	16,700.00
08/03/2022	-	-	-	7	900	7,596.00
09/03/2022	7	600	4,920.00	-	-	-
10/03/2022	7	900	7,083.00	5	500	4,150.00
11/03/2022	1	1	8.00	8	800	6,480.00
14/03/2022	21	3,250	24,472.50	-	-	-
15/03/2022	2	500	3,625.00	8	1,250	9,162.50
16/03/2022	-	-	-	1	250	1,825.00
17/03/2022	8	500	3,610.00	1	180	1,305.00
18/03/2022	7	1,000	7,030.00	-	-	-
21/03/2022	12	939	6,441.54	1	1	7.10
22/03/2022	8	500	3,400.00	3	200	1,380.00
23/03/2022	5	564	3,722.40	-	-	-
24/03/2022	-	-	-	1	1	6.70
25/03/2022	2	436	2,851.44	2	254	1,701.80
28/03/2022	8	1,000	6,490.00	3	102	673.20
29/03/2022	8	652	4,172.80	5	1,000	6,480.00
30/03/2022	2	17	108.80	7	1,243	8,216.23
31/03/2022	2	250	1,625.00	1	250	1,675.00
01/04/2022	3	558	3,593.52	2	250	1,625.00
04/04/2022	4	400	2,584.00	-	-	-
05/04/2022	-	-	-	7	1,251	8,331.66
06/04/2022	2	350	2,334.50	1	1	6.80
07/04/2022	2	450	2,952.00	1	149	983.40
08/04/2022	5	320	2,076.80	2	11	72.60
11/04/2022	3	499	3,318.35	10	1,840	12,843.20
12/04/2022	4	266	1,806.14	1	1	6.80
13/04/2022	2	235	1,574.50	-	-	-
14/04/2022	4	166	1,112.20	2	11	74.80
19/04/2022	4	500	3,625.00	17	3,455	26,707.15
20/04/2022	8	1,250	9,325.00	5	1,000	7,880.00
21/04/2022	4	371	2,808.47	11	1,945	15,209.90
22/04/2022	14	755	5,911.65	2	500	3,975.00
25/04/2022	11	704	5,498.24	-	-	-
26/04/2022	4	267	2,053.23	4	750	5,947.50
27/04/2022	4	233	1,770.80	-	-	-
28/04/2022	3	80	600.00	1	1	7.70
29/04/2022	3	50	370.00	4	751	5,782.70
02/05/2022	-	-	-	13	2,100	16,884.00
03/05/2022	-	-	-	2	123	1,008.60
04/05/2022	5	261	2,088.00	9	1,378	11,451.18
05/05/2022	5	395	3,160.00	1	250	2,050.00
06/05/2022	10	1,041	8,244.72	1	1	8.20
09/05/2022	2	210	1,617.00	3	266	2,101.40
10/05/2022	2	126	970.20	5	228	1,778.40
11/05/2022	-	-	-	3	250	1,950.00
12/05/2022	4	251	1,932.70	1	1	7.72
13/05/2022	4	250	1,925.00	1	250	1,950.00
16/05/2022	10	1,200	8,892.00	3	500	3,825.00
17/05/2022	8	752	5,640.00	1	1	7.72
18/05/2022	1	250	1,825.00	1	1	7.60
19/05/2022	2	250	1,825.00	-	-	-
20/05/2022	16	2,250	15,682.50	3	251	1,807.20
23/05/2022	5	250	1,700.00	6	162	1,117.80
24/05/2022	2	16	107.20	2	251	1,706.80
25/05/2022	-	-	-	6	1,000	7,050.00
26/05/2022	-	-	-	5	250	1,775.00
27/05/2022	1	1	7.10	1	1	7.10
30/05/2022	6	500	3,525.00	2	101	727.20
31/05/2022	2	56	392.00	3	301	2,143.12
01/06/2022	6	696	4,844.16	1	1	7.02
02/06/2022	2	485	3,273.75	2	162	1,117.80
03/06/2022	2	500	3,400.00	8	888	6,224.88
06/06/2022	1	15	105.00	2	30	213.00
07/06/2022	6	245	1,715.00	1	1	7.08
08/06/2022	7	742	5,119.80	1	1	7.04
09/06/2022	1	250	1,700.00	-	-	-
10/06/2022	2	250	1,700.00	1	10	69.00
13/06/2022	1	250	1,675.00	2	16	108.96
14/06/2022	6	251	1,681.70	3	336	2,284.80
15/06/2022	5	251	1,681.70	4	20	136.00
16/06/2022	1	15	100.50	-	-	-
17/06/2022	2	31	207.70	-	-	-
20/06/2022	2	17	113.90	6	861	5,975.34
21/06/2022	4	251	1,731.90	2	10	70.00
22/06/2022	3	17	115.60	2	2	13.78
23/06/2022	2	17	115.60	5	170	1,173.00
24/06/2022	4	19	129.20	3	12	82.80
27/06/2022	1	15	102.00	2	68	469.20
28/06/2022	1	1	6.88	1	1	6.88
29/06/2022	3	185	1,258.00	1	1	6.84
30/06/2022	-	-	-	4	250	1,725.00